Osteosarcoma - Pipeline Review, H2 2016

Date: August 17, 2016
Pages: 223
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: O52BF4A8A59EN
Leaflet:

Download PDF Leaflet

Osteosarcoma - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Osteosarcoma - Pipeline Review, H2 2016’, provides an overview of the Osteosarcoma pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Osteosarcoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Osteosarcoma and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope
  • The report provides a snapshot of the global therapeutic landscape of Osteosarcoma
  • The report reviews pipeline therapeutics for Osteosarcoma by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Osteosarcoma therapeutics and enlists all their major and minor projects
  • The report assesses Osteosarcoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Osteosarcoma
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Osteosarcoma
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Osteosarcoma pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Osteosarcoma Overview
Therapeutics Development
Pipeline Products for Osteosarcoma - Overview
Pipeline Products for Osteosarcoma - Comparative Analysis
Osteosarcoma - Therapeutics under Development by Companies
Osteosarcoma - Therapeutics under Investigation by Universities/Institutes
Osteosarcoma - Pipeline Products Glance
Clinical Stage Products
Early Stage Products
Osteosarcoma - Products under Development by Companies
Osteosarcoma - Products under Investigation by Universities/Institutes
Osteosarcoma - Companies Involved in Therapeutics Development
Advaxis, Inc.
Amgen Inc.
AVEO Pharmaceuticals, Inc.
Bayer AG
Bellicum Pharmaceuticals, Inc.
Celldex Therapeutics, Inc.
CytRx Corporation
Eleison Pharmaceuticals LLC
Exelixis, Inc.
Isofol Medical AB
MediaPharma s.r.l.
Merck & Co., Inc.
Merrimack Pharmaceuticals, Inc.
Netris Pharma S.A.S.
Novartis AG
Oncolys BioPharma Inc
Pfizer Inc.
Shionogi & Co., Ltd.
Teijin Pharma Limited
United Therapeutics Corporation
Osteosarcoma - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
3D-QM - DRUG PROFILE
Product Description
Mechanism Of Action
R&D Progress
3D-QMS - DRUG PROFILE
Product Description
Mechanism Of Action
R&D Progress
ADXS-HER2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
aldoxorubicin hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AM-7209 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AU-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AV-203 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
axitinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cabozantinib s-malate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cellular Immunotherapy for GD2 Expressing Solid Tumors - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cellular Immunotherapy to Target HER2 for Glioblastoma Multiforme and Osteosarcoma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cellular Immunotherapy to Target MAGE-A1, MAGE-A3 and NY-ESO-1 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
celyvir - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CGS-200 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cisplatin SR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dihydroartemisinin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dinutuximab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
everolimus - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
glembatumumab vedotin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
irinotecan hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ligerin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LLL-12 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Modufolin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody for Osteosarcoma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Inhibit GD2 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Target Ganglioside GD2 for Neuroblastoma and Osteosarcoma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MPE-8.3 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NP-137 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OBP-702 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Oligonucleotides to Inhibit Thymidylate Synthase and Dihydrofolate Reductase for Osteosarcoma and Colon Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pazopanib hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pembrolizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Peptide to Target COX-2 and MAS-GPCR for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
radium Ra 223 dichloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RSF-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
S-588410 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SEN-461 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize Vitamin D3 Receptor for Osteosarcoma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit CaMKII for Osteosarcoma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
T-2GES - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine for Osteosarcoma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Osteosarcoma - Dormant Projects
Osteosarcoma - Discontinued Products
Osteosarcoma - Product Development Milestones
Featured News & Press Releases
Apr 28, 2016: FDA Grants Advaxis Fast Track Designation for ADXS-HER2 for Patients with Newly-Diagnosed, Non-Metastatic, Surgically-Resectable Osteosarcoma
Apr 20, 2016: Celldex Therapeutics Presents Data Supporting the Clinical Development of Glembatumumab Vedotin at the AACR Annual Meeting 2016
Apr 13, 2016: Sarcoma Foundation of America Honors Advaxis for Advancements in Immunotherapy Platform
Mar 23, 2016: Advaxis Hosts Research Reception to Review Late-Breaking ADXS-HER2 at AACR Abstract
Mar 21, 2016: Survival Results with Advaxis HER2 Targeted Immunotherapy in Canine Osteosarcoma Published in Clinical Cancer Research
Mar 16, 2016: Merrimack to Present on ONIVYDE (irinotecan liposome injection) at the 2016 American Association for Cancer Research Annual Meeting
Jan 19, 2016: Advaxis Expands Intellectual Property for Lm Technology Platform
Dec 01, 2015: Advaxis Receives Orphan Drug Designation in the European Union for ADXS-HER2 for the Treatment of Osteosarcoma
Nov 30, 2015: CapGenesis Files Five Orphan Drug Designation Requests with the FDA and EMA for CGS-200 as a Topical Analgesic
Jul 21, 2015: Advaxis Expands Intellectual Property for Lm Technology Platform in HER2
May 04, 2015: CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers
May 01, 2015: Eleison Announces Successful Completion of Stage 1 of its Phase II Trial of ILC (Inhaled Lipid-complexed Cisplatin) for Pediatric Bone Cancer
Apr 28, 2015: Advaxis Enhances Lm-LLO Cancer Immunotherapy Intellectual Property With USPTO Patent Addressing ADXS-HER2
Nov 04, 2014: Advaxis to Present Data of ADXS-cHER2 at the Society for Immunotherapy of Cancer 29th Annual Meeting
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Osteosarcoma, H2 2016
Number of Products under Development for Osteosarcoma - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Investigation by Universities/Institutes, H2 2016
Osteosarcoma - Pipeline by Advaxis, Inc., H2 2016
Osteosarcoma - Pipeline by Amgen Inc., H2 2016
Osteosarcoma - Pipeline by AVEO Pharmaceuticals, Inc., H2 2016
Osteosarcoma - Pipeline by Bayer AG, H2 2016
Osteosarcoma - Pipeline by Bellicum Pharmaceuticals, Inc., H2 2016
Osteosarcoma - Pipeline by Celldex Therapeutics, Inc., H2 2016
Osteosarcoma - Pipeline by CytRx Corporation, H2 2016
Osteosarcoma - Pipeline by Eleison Pharmaceuticals LLC, H2 2016
Osteosarcoma - Pipeline by Exelixis, Inc., H2 2016
Osteosarcoma - Pipeline by Isofol Medical AB, H2 2016
Osteosarcoma - Pipeline by MediaPharma s.r.l., H2 2016
Osteosarcoma - Pipeline by Merck & Co., Inc., H2 2016
Osteosarcoma - Pipeline by Merrimack Pharmaceuticals, Inc., H2 2016
Osteosarcoma - Pipeline by Netris Pharma S.A.S., H2 2016
Osteosarcoma - Pipeline by Novartis AG, H2 2016
Osteosarcoma - Pipeline by Oncolys BioPharma Inc, H2 2016
Osteosarcoma - Pipeline by Pfizer Inc., H2 2016
Osteosarcoma - Pipeline by Shionogi & Co., Ltd., H2 2016
Osteosarcoma - Pipeline by Teijin Pharma Limited, H2 2016
Osteosarcoma - Pipeline by United Therapeutics Corporation, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Osteosarcoma - Dormant Projects, H2 2016
Osteosarcoma - Dormant Projects (Contd..1), H2 2016
Osteosarcoma - Discontinued Products, H2 2016

LIST OF FIGURES

Number of Products under Development for Osteosarcoma, H2 2016
Number of Products under Development for Osteosarcoma - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Types, H2 2016
Skip to top


Osteosarcoma - Pipeline Review, H1 2016 US$ 1,700.00 Mar, 2016 · 306 pages
Sutro Biopharma, Inc. - Product Pipeline Review - 2016 US$ 1,275.00 Feb, 2016 · 34 pages
Wegener Polyangiitis - Pipeline Review, H2 2015 US$ 1,700.00 Dec, 2015 · 66 pages
Adenovirus Infections - Pipeline Review, H1 2014 US$ 1,500.00 Jun, 2014 · 64 pages
Seikagaku Corporation - Product Pipeline Review - 2015 US$ 1,275.00 Nov, 2015 · 29 pages

Ask Your Question

Osteosarcoma - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: